Zhengye Biotechnology Holding Limited (ZYBT)

ZYBT Income Statement

Financials in millions CNY. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021
Revenue	253.77	260.27	214.07
Revenue Growth (YoY)	-	21.58%	-
Cost of Revenue	-	106.75	88.67
Gross Profit	149.13	153.52	125.39
Selling, General & Admin	-	63.56	58.19
Research & Development	-	13.42	11.37
Other Operating Expenses	0	10.7	3.45
Operating Expenses	-	87.69	73.01
Operating Income	62.61	65.83	52.38
Interest Expense / Income	-	2.73	0.93
Other Expense / Income	10.35	-0.81	-1.62
Pretax Income	43.82	54.91	45.56
Income Tax	-	8.17	6.6
Net Income	52.26	55.74	46.47
Net Income Common	43.82	46.74	38.96
Net Income Growth	-	19.96%	-
Free Cash Flow	8.93	-9.99	5.41
Gross Margin	58.76%	58.98%	58.58%
Operating Margin	24.67%	25.29%	24.47%
Profit Margin	17.27%	17.96%	18.20%
Free Cash Flow Margin	3.52%	-3.84%	2.53%
Effective Tax Rate	-	14.88%	14.48%
EBITDA	-	85.44	70.01
EBITDA Margin	-	32.83%	32.71%
Depreciation & Amortization	-	18.8	16.01
EBIT	-	66.64	54
EBIT Margin	-	25.60%	25.23%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).